MIST
Milestone Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · CA
$0.70
−1.02%Oct 19, 2026, 12:00 UTC
Milestone Pharmaceuticals announced that data and program updates on CARDAMYST (etripamil) nasal spray will be presented at three upcoming cardiovascular medical meetings.
Source:Oct 9, 2026, 12:00 UTC
Milestone Pharmaceuticals Inc. announced that the first European participant had enrolled in its ReVeRA-301 Phase 3 trial evaluating etripamil nasal spray for AFib-RVR, with the Dutch Cardiovascular Investigator Network leading European enrollment.
Source:Sep 24, 2026, 12:00 UTC
Milestone Pharmaceuticals announced that the Montreal Heart Institute, the first activated Canadian site for the ReVeRA-301 Phase 3 pivotal trial, enrolled its first patient in the trial evaluating etripamil nasal spray for atrial fibrillation with rapid ventricular rate.
Source:Sep 3, 2026, 05:14 UTC
China's National Medical Products Administration approved the launch of Milestone Pharmaceuticals Inc.'s etripamil nasal spray (brand name: Xingbituo) for treating acute episodes of paroxysmal supraventricular tachycardia in adults.
Aug 21, 2026, 12:00 UTC
Milestone Pharmaceuticals initiated the pivotal Phase 3 ReVeRA-301 trial of its etripamil nasal spray for self-administered treatment of atrial fibrillation with rapid ventricular rate (AFib-RVR).
Source:Aug 12, 2026, 00:00 UTC
Milestone Pharmaceuticals Inc. reported Q2 2026 financial results with product revenue of $0.6 million, a net loss of $28.6 million, and diluted EPS of -$0.21, as of June 30, 2026.
Jul 3, 2026, 01:30 UTC
Milestone Pharmaceuticals granted equity awards to six new employees as a material inducement to their hiring.
Source:Jun 15, 2026, 00:00 UTC
Milestone Pharmaceuticals Inc. elected Joseph Oliveto, Stuart M. Duty, Seth H.Z. Fischer, Lisa M. Giles, and Joseph C. Papa as directors effective June 10, 2026.